

Product datasheet for **SR304888**

Cardiac Troponin I (TNNI3) Human siRNA Oligo Duplex (Locus ID 7137)

Product data:

Product Type:	siRNA Oligo Duplexes
Purity:	HPLC purified
Quality Control:	Tested by ESI-MS
Sequences:	Available with shipment
Stability:	One year from date of shipment when stored at -20°C.
# of transfections:	Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final conc. 10 nM).
Note:	Single siRNA duplex (10nmol) can be ordered.
RefSeq:	NM_000363
UniProt ID:	P19429
Synonyms:	CMD1FF; CMD2A; CMH7; cTnI; RCM1; TNNC1
Components:	TNNI3 (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each (Locus ID 7137) Included - SR30004, Trilencer-27 Universal Scrambled Negative Control siRNA Duplex - 2 nmol Included - SR30005, RNase free siRNA Duplex Resuspension Buffer - 2 ml
Summary:	<p>Troponin I (TnI), along with troponin T (TnT) and troponin C (TnC), is one of 3 subunits that form the troponin complex of the thin filaments of striated muscle. TnI is the inhibitory subunit; blocking actin-myosin interactions and thereby mediating striated muscle relaxation. The TnI subfamily contains three genes: TnI-skeletal-fast-twitch, TnI-skeletal-slow-twitch, and TnI-cardiac. This gene encodes the TnI-cardiac protein and is exclusively expressed in cardiac muscle tissues. Mutations in this gene cause familial hypertrophic cardiomyopathy type 7 (CMH7) and familial restrictive cardiomyopathy (RCM). Troponin I is useful in making a diagnosis of heart failure, and of ischemic heart disease. An elevated level of troponin is also now used as indicator of acute myocardial injury in patients hospitalized with moderate/severe Coronavirus Disease 2019 (COVID-19). Such elevation has also been associated with higher risk of mortality in cardiovascular disease patients hospitalized due to COVID-19. [provided by RefSeq, Aug 2020]</p>



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that at least two of the three Dicer-Substrate duplexes in the kit will provide at least 70% or more knockdown of the target mRNA when used at 10 nM concentration by quantitative RT-PCR when the TYE-563 fluorescent transfection control duplex (cat# SR30002) indicates that >90% of the cells have been transfected and the HPRT positive control (cat# SR30003) provides 90% knockdown efficiency.

For non-conforming siRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the siRNA kit. To arrange for a free replacement with newly designed duplexes, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled siRNA control (quantitative RT-PCR data required).